(Q33813750)

29 July 2017

title

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes (English)

1 reference

29 July 2017

main subject

phase I clinical trial

0 references

author

Jaroslaw P. Maciejewski

11

object named as

Jaroslaw P Maciejewski

1 reference

29 July 2017

Mikkael A Sekeres

1

1 reference

29 July 2017

Alan F List

2

1 reference

29 July 2017

David Cuthbertson

3

1 reference

29 July 2017

Ronald Paquette

4

1 reference

29 July 2017

Rebecca Ganetzky

5

1 reference

29 July 2017

Deborah Latham

6

1 reference

29 July 2017

Katarina Paulic

7

1 reference

29 July 2017

Manuel Afable

8

1 reference

29 July 2017

Hussain I Saba

9

1 reference

29 July 2017

Thomas P Loughran

10

1 reference

29 July 2017

language of work or name

English

0 references

publication date

30 March 2010

1 reference

Journal of Clinical Oncology

29 July 2017

published in

1 reference

29 July 2017

volume

28

1 reference

29 July 2017

issue

13

1 reference

29 July 2017

page(s)

2253-2258

1 reference

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Efficacy of lenalidomide in myelodysplastic syndromes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Myelodysplastic syndromes.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

The World Health Organization (WHO) classification of the myeloid neoplasms

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

International scoring system for evaluating prognosis in myelodysplastic syndromes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Proposals for the classification of the myelodysplastic syndromes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2860439

Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20354132

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Myelodysplastic syndromes: incidence and survival in the United States

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20354132

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20354132

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2009.26.0745

1 reference

29 July 2017

1 reference

29 July 2017

1 reference